<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385617</url>
  </required_header>
  <id_info>
    <org_study_id>CRFSJ 0026</org_study_id>
    <secondary_id>REC 2011/27/01</secondary_id>
    <nct_id>NCT02385617</nct_id>
  </id_info>
  <brief_title>Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer</brief_title>
  <official_title>Food Intake and Gut Hormone Release in Patients in Cancer Remission Who Have Undergone Upper Gastrointestinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. James's Hospital, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dublin, Trinity College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. James's Hospital, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvements to treatment strategies for patients upper gastrointestinal cancers have
      produced an increasing population of people who remain free from disease recurrence in the
      long term. Weight loss and nutritional problems are common among patients who attain
      long-term remission and cure after surgery for upper gastrointestinal cancers. However, the
      mechanisms underlying these problems are not well understood. In this study the investigators
      aim to determine whether reduced food intake after upper gastrointestinal surgery is caused
      by early satiety related to exaggerated post-prandial gut hormone responses.

      This is a randomized, double-blind, placebo controlled, crossover study of the effect of
      100μg octreotide SC on ad libitum food intake in patients free from complications or
      recurrence at least one year post-oesophagectomy, gastrectomy or pancreaticoduodenectomy. A
      comparator group of age, weight and gender matched subjects will be studied concurrently, and
      caloric intake and subjective symptom scores after administration of octreotide versus
      placebo among surgical and comparator subjects will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum calorie intake</measure>
    <time_frame>1 hour</time_frame>
    <description>Total kcals consumed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-prandial satiety gut hormone response</measure>
    <time_frame>2 hours</time_frame>
    <description>GLP-1, PYY, OXM plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective symptom scores</measure>
    <time_frame>3 hours</time_frame>
    <description>Modified visual analogue scale scores</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <condition>Weight Loss</condition>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind single dose placebo-octreotide crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind single dose placebo-octreotide crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - no surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blind single dose placebo-octreotide crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double blind single dose placebo-octreotide crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating</description>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_label>Total gastrectomy</arm_group_label>
    <arm_group_label>Control - no surgery</arm_group_label>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
    <other_name>Sandostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating</description>
    <arm_group_label>Esophagectomy</arm_group_label>
    <arm_group_label>Total gastrectomy</arm_group_label>
    <arm_group_label>Control - no surgery</arm_group_label>
    <arm_group_label>Pancreaticoduodenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Surgical procedure: Two-stage, three-stage or transhiatal oesophagectomy with gastric
             conduit reconstruction and pyloroplasty, total gastrectomy with Roux-en-Y
             reconstruction, pancreaticodueodenectomy, or matched unoperated healthy controls

          2. At least one year in remission post-resection (surgical groups)

        Exclusion Criteria:

          1. Pregnancy, breastfeeding

          2. Significant and persistent chemoradiotherapy and/or surgical complication

          3. Other previous upper gastrointestinal surgery

          4. Significant dysphagia or odynophagia, unable to eat

          5. Other disease or medications which may affect satiety gut hormone responses

          6. Active and significant psychiatric illness including substance misuse

          7. Cognitive or communication issues or any factors affecting capacity to consent to
             participation

          8. History of significant food allergy, certain dietary restrictions

          9. Confirmed or suspected residual or recurrent disease after surgery, second primary
             malignancy

         10. Other reconstruction (eg colonic or jejunal interposition)

         11. Any contraindication to octreotide administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John V Reynolds, MCh, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, St. James's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust-Health Research Board Clinical Research Facility, St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrosurgical Laboratory, Sahlgrenska Academy, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.sjhcrf.ie/</url>
    <description>Wellcome Trust-HRB Clinical Research Facility</description>
  </link>
  <link>
    <url>https://medicine.tcd.ie/surgery/</url>
    <description>Department of Surgery, Trinity College Dublin</description>
  </link>
  <link>
    <url>http://www.ucd.ie/conway/</url>
    <description>Conway Institute of Biomolecular and Biomedical Research</description>
  </link>
  <link>
    <url>http://www.stjames.ie/</url>
    <description>St James's Hospital, Dublin</description>
  </link>
  <link>
    <url>http://www.gu.se/english</url>
    <description>University of Gothenburg</description>
  </link>
  <reference>
    <citation>le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olbers T. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007 Nov;246(5):780-5.</citation>
    <PMID>17968169</PMID>
  </reference>
  <reference>
    <citation>Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007 Dec;94(12):1496-500.</citation>
    <PMID>17668914</PMID>
  </reference>
  <reference>
    <citation>Haverkort EB, Binnekade JM, de Haan RJ, Busch OR, van Berge Henegouwen MI, Gouma DJ. Suboptimal intake of nutrients after esophagectomy with gastric tube reconstruction. J Acad Nutr Diet. 2012 Jul;112(7):1080-7. doi: 10.1016/j.jand.2012.03.032.</citation>
    <PMID>22889637</PMID>
  </reference>
  <reference>
    <citation>Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life for disease-free esophageal cancer patients. World J Surg. 2011 Aug;35(8):1853-60. doi: 10.1007/s00268-011-1123-6.</citation>
    <PMID>21553202</PMID>
  </reference>
  <reference>
    <citation>Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N, Byrne PJ. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg. 2006 Sep;93(9):1084-90.</citation>
    <PMID>16779881</PMID>
  </reference>
  <reference>
    <citation>Miholic J, Orskov C, Holst JJ, Kotzerke J, Pichlmayr R. Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. Digestion. 1993;54(2):73-8.</citation>
    <PMID>8319842</PMID>
  </reference>
  <reference>
    <citation>Miras AD, le Roux CW. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):575-84. doi: 10.1038/nrgastro.2013.119. Epub 2013 Jul 9. Review.</citation>
    <PMID>23835488</PMID>
  </reference>
  <reference>
    <citation>Koizumi M, Hosoya Y, Dezaki K, Yada T, Hosoda H, Kangawa K, Nagai H, Lefor AT, Sata N, Yasuda Y. Postoperative weight loss does not resolve after esophagectomy despite normal serum ghrelin levels. Ann Thorac Surg. 2011 Apr;91(4):1032-7. doi: 10.1016/j.athoracsur.2010.11.072.</citation>
    <PMID>21440118</PMID>
  </reference>
  <reference>
    <citation>Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Nakajima H, Hosoda H, Kangawa K, Sasakuma F, Motoori M, Imaoka S. Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 2006 Jun;139(6):797-805.</citation>
    <PMID>16782437</PMID>
  </reference>
  <reference>
    <citation>Miyazaki T, Tanaka N, Hirai H, Yokobori T, Sano A, Sakai M, Inose T, Sohda M, Nakajima M, Fukuchi M, Kato H, Kuwano H. Ghrelin level and body weight loss after esophagectomy for esophageal cancer. J Surg Res. 2012 Jul;176(1):74-8. doi: 10.1016/j.jss.2011.09.016. Epub 2011 Oct 3.</citation>
    <PMID>22137988</PMID>
  </reference>
  <results_reference>
    <citation>Elliott JA, Jackson S, King S, McHugh R, Docherty NG, Reynolds JV, le Roux CW. Gut Hormone Suppression Increases Food Intake After Esophagectomy With Gastric Conduit Reconstruction. Ann Surg. 2015 Nov;262(5):824-29; discussion 829-30. doi: 10.1097/SLA.0000000000001465.</citation>
    <PMID>26583672</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. James's Hospital, Ireland</investigator_affiliation>
    <investigator_full_name>Dr Jessie A Elliott</investigator_full_name>
    <investigator_title>Surgical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Glucagon-Like Peptide 1</keyword>
  <keyword>Peptide YY</keyword>
  <keyword>Ghrelin</keyword>
  <keyword>Satiety Response</keyword>
  <keyword>Appetite</keyword>
  <keyword>Hunger</keyword>
  <keyword>Somatostatin</keyword>
  <keyword>Octreotide</keyword>
  <keyword>Anastomosis, Roux-en-Y</keyword>
  <keyword>Digestive System Surgical Procedures</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Enteroendocrine Cells</keyword>
  <keyword>Gastrointestinal Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

